Alkermes Plc (NASDAQ: ALKS)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Alkermes Plc Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Alkermes Plc Company Info
A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease.
News & Analysis
The drugmaker beat Wall Street's expectations with its Q1 results.
The biotech smashed analyst estimates in its final quarter of 2021.
Johnson & Johnson partly ended two licensing agreements with the company.
An agreement with an activist investor capped a busy month.
Keeping track of upcoming events is important.
The biotech posted a big year-over-year sales decline. But there was a good reason for it.
The biotech has a plan to increase profitability.
A patent case win for its partner Biogen will give the duo time to convince multiple sclerosis patients to switch from Tecfidera to Vumerity.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 04/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
ALKS earnings call for the period ending June 30, 2022.
ALKS earnings call for the period ending March 31, 2022.
ALKS earnings call for the period ending December 31, 2021.
ALKS earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.